CClinicalTrials.gg
Sign In
Status unknownNCT03047889Updated Feb 9, 2017

A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast

An observational study in Advanced Breast Cancer, sponsored by Chinese Academy of Medical Sciences. Status unknown at 19 sites in China. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-02-09.

Sponsored by Chinese Academy of Medical Sciences · Observational

The sponsor has not verified this record recently (last verified Feb 2017), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
4,200
Ages
18 Years to 99 Years
Sex
Female
01

Study summary

To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results

Read the detailed description

In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references for standardized treatment therapy, and to improve the quality of life and prolong survival time.

To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness

02

Conditions studied

  • Advanced Breast Cancer
03

In context

Lead sponsor

Chinese Academy of Medical Sciences is the lead sponsor of 235 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

A total of 21 hospitals were selected in this study. The investigators recruited 4200 advanced BC cases, who were first diagnosed with advanced BC from January 1st, 2012 to December 31st, 2014 from these hospitals.

Inclusion criteria

  • diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014
  • complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.

Exclusion criteria

Exclusion Criteria:

  • no available medical record
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
4,200 participants (estimated)
Patient registry
No

Interventions

  • Drugstandard therapy

    standard therapy for advanced/metastatic breast cancer

06

What researchers measure

Primary outcomes

  1. Survival status at 3 years

    percentage of patients still alive at 3 years

    Time frame: 3 years

Secondary outcomes

  1. PFS

    Progression-free survival of first line therapy

    Time frame: 3 years

  2. Survival status at 5 years

    percentage of patients still alive at 5 years

    Time frame: 3 years

07

Study locations

1 of 19 sites recruiting
  • The 307th Hospital of Military Medical Sciences
    Beijing, China
    • Zefei Jiang · Contact
    Not yet recruiting
  • Sichuan Cancer Hospital and Institute
    Chengdu, China
    • Hui Li · Contact
    Not yet recruiting
  • The First Affliated Hospital of Chongqing Medical University
    Chongqing, China
    • Hongyuan Li · Contact
    Not yet recruiting
  • FuZhou General Hospital of National Miltary Command
    Fuzhou, China
    • Xuenong Ouyang · Contact
    Not yet recruiting
  • Sun Yat-Sen University Cancer Center
    Guangzhou, China
    • Shuseng Wang · Contact
    Not yet recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, China
    • Li Cai · Contact
    Not yet recruiting
  • Henan Cancer Hospital
    Henan, China
    • Min Yan · Contact
    Not yet recruiting
  • Hunan Cancer Hospital
    Hunan, China
    • Quchang Ouyang · Contact
    Not yet recruiting
  • Jiangsu Provinces hospital
    Jiangsu, China
    • Yongmei Yin · Contact
    Not yet recruiting
  • Tumor Hospital of Yunnan Province
    Kunming, China
    • Runxiang Yang · Contact
    Not yet recruiting
  • Liaoning Cancer Hospital, Zhejiang Cancer Hospital
    Liaoning, China
    • Tao Sun · Contact
    Not yet recruiting
  • General Hospital of NingXia Medical University
    Ningxia, China
    • Xinlan Liu · Contact
    Recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, China
    • Xichun Hu · Contact
    Not yet recruiting
  • The First Hospital of China Medical University
    Shenyang, China
    • Yuee Teng · Contact
    Not yet recruiting
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, China
    • Zhongsheng Tong · Contact
    Not yet recruiting
  • Wuhan Union Hospital
    Wuhan, China
    • Tao Huang · Contact
    Not yet recruiting
  • The First Hospital of Xi'an Jiaotong University
    Xi'an, China
    • Jianjun He · Contact
    Not yet recruiting
  • Xinjiang Medical University Cancer Hospital
    Xinjiang, China
    • Shune Yang · Contact
    Not yet recruiting
  • FuJian Provincial Cancer Hospital
    Zhengzhou, China
    • Jian Liu · Contact
    Not yet recruiting
08

References and documents

Publications

  • Han YQ, Yi ZB, Yu P, Wang WN, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Ouyang XN, He JJ, Liu XL, Yang SE, Qiao YL, Fan JH, Wang JY, Xu BH. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. J Oncol. 2021 Sep 15;2021:6621722. doi: 10.1155/2021/6621722. eCollection 2021. PubMed 34567118 ↗
  • Guo F, Yi Z, Wang W, Han Y, Yu P, Zhang S, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Fan J, Qiao Y, Wang J, Xu B. Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation-wide multicenter study. Cancer Med. 2021 Oct;10(19):6744-6761. doi: 10.1002/cam4.4215. Epub 2021 Sep 2. PubMed 34472719 ↗
  • Wu Y, Han Y, Yu P, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, He J, Liu X, Yang S, Qiao Y, Fan J, Wang J, Xu B. Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Front Oncol. 2021 Feb 11;10:599604. doi: 10.3389/fonc.2020.599604. eCollection 2020. PubMed 33643905 ↗
  • Yi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Chen X, He JJ, Liu XL, Yang SE, Wang JY, Fan JH, Qiao YL, Xu BH. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2021 Feb 1;148(3):692-701. doi: 10.1002/ijc.33227. Epub 2020 Aug 19. PubMed 32700765 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03047889
Lead sponsor
Chinese Academy of Medical Sciences
Responsible party
Binghe Xu (Professor, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Feb 9, 2017
Start date
Apr 2016
Primary completion
Apr 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Feb 9, 2017

Study contacts

Binghe Xu
Contact
syhiir@126.com
Binghe Xu
principal investigator · Chinese Academy of Medical Sciences
Youlin Qiao
principal investigator · Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Chinese Academy of Medical Sciences

Start the discussion